A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects

Inclusion Criteria: * Subjects voluntarily joined the study, sign informed consent form before the study and fully understand the study content * Healthy subjects aged between 18 and 55 years (inclusive),both male and female * The male subject should weigh at least 50kg, the female subject should weigh at least 45kg. And body mass index (BMI) within 19\~28 kg/m2 * Inhalation administration training qualified. * During the screening period, the percentage of predicted value for forced expiratory volume in one second (FEV1) before bronchodilator administration is ≥80%, and FEV1/forced vital capacity (FVC) is ≥70%. * Have no pregnancy plan and voluntarily take effective contraception measures from time of screening to at least 90 days after the last dose (subjects and their partners) Exclusion Criteria: * Individuals with a history of glaucoma, functional constipation, benign prostatic hyperplasia, urinary tract obstruction, etc * Current history of active tuberculosis, bronchiectasis or other non-specific lung diseases * People who have received or are planning to receive inactive or active vaccines during the 30 days prior to the screening period and the entire study period * Any history of drug allergies, Individuals with a specific history of allergies or allergies * Had undergone surgery within 1 month prior to screening period or expected to undergo surgery during the study period * People with special dietary requirements who cannot follow a standard diet; * People who have potential difficulty in blood collection, or have a history of halo needles or blood sickness； * History of drug or narcotics abuse or a positive result of urine drug test at screening * People who have abnormal and clinically significant results in vital signs, physical examination, laboratory tests, Chest radiograph and abdominal ultrasound during screening period * Subjects Positive for Any of Hepatitis B Virus Surface Antigen (HBsAg), Hepatitis C Virus Antibody (Anti-HCV), Human Immunodeficiency Virus Antibody (Anti-HIV), and Treponema Pallidum Antibody (Anti-TP) * Pregnant or lactating women or those with positive blood pregnancy test results during the screening period